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Background: Primary lung graft failure is common, and current lung
preservation strategies are suboptimal. Because the decline in lung lev-
els of cyclic adenosine monophosphate and cyclic guanosine monophos-
phate during preservation could enhance adhesiveness of endothelial
cells for leukocytes as well as increase vascular permeability and vaso-
constriction, we hypothesized that buttressing these levels by means of a
preservation solution would significantly improve lung preservation.
Methods: An orthotopic rat left lung transplantation model was used.
Lungs were harvested from male Lewis rats and preserved for 6 hours
at 4°C with (1) Euro-Collins solution (n = 8); (2) University of Wisconsin
solution (n = 8); (3) low-potassium dextran glucose solution (n = 8); (4)
Columbia University solution (n = 8), which contains a cyclic adenosine
monophosphate analog (dibutyryl cyclic adenosine monophosphate)
and a nitric oxide donor (nitroglycerin) to buttress cyclic guanosine
monophosphate levels; or (5) Columbia University solution without
cyclic adenosine monophosphate or nitroglycerin (n = 8). PaO2, pul-
monary vascular resistance, and recipient survival were evaluated 30
minutes after left lung transplantation and removal of the nontrans-
planted right lung from the pulmonary circulation. Results: Among all
groups studied, grafts stored with Columbia University solution demon-
strated the highest PaO2 (355 ± 25 mm Hg for Columbia University solu-
tion versus 95 ± 22 mm Hg for Euro-Collins solution, P < .01, 172 ± 55
mm Hg for University of Wisconsin solution, P < .05, 76 ± 15 mm Hg for
low-potassium dextran glucose solution, P < .01, and 82 ± 25 mm Hg for
Columbia University solution without cyclic adenosine monophosphate
or nitroglycerin, P < .01) and the lowest pulmonary vascular resistances
(1 ± 0.2 mm Hg · mL–1 · min–1 for Columbia University solution versus
12 ± 4 mm Hg · mL–1 · min–1 for Euro-Collins solution, P < .01, 9 ± 2 mm
Hg · mL–1 · min–1 for University of Wisconsin solution, 14 ± 6 mm Hg ·
mL–1 · min–1 for low-potassium dextran glucose solution, P < .01, and 8
± 2 mm Hg · mL–1 · min–1 for Columbia University solution without
cyclic adenosine monophosphate and nitroglycerin). These functional
and hemodynamic improvements provided by Columbia University
solution were accompanied by decreased graft leukostasis and
decreased recipient tumor necrosis factor a and interleukin 1a levels
compared with the other groups. In toto, these improvements translat-
ed into superior survival among recipients of Columbia University solu-
tion–preserved grafts (100% for Columbia University solution, 37% for
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T he transplantation of solid organs is becoming anincreasingly important therapeutic option for
patients with end-stage disease of a single organ sys-
tem. Among the solid organs that are transplanted, the
experience with lung transplantation has arguably been
the worst, with only about 70% of patients surviving
for 1 year.1 One of the major impediments in lung
transplantation is the exquisite vulnerability of the
lungs to harvest, storage, and transplantation proce-
dures, with a resulting incidence of primary graft fail-
ure as high as approximately 15% within 30 days after
transplantation.1,2 New mechanistic insights into rea-
sons underlying primary lung graft failure, which could
lead to means for its prevention, would come as a wel-
come relief to the transplantation community.
Designs of lung preservation solutions in current
clinical use have centered on maintaining physico-
chemical properties of the ex vivo organ. We hypothe-
sized that although tonicity, osmolality, and pH may be
important properties of an optimal preservation solu-
tion, strategies to maintain endothelial homeostatic
properties are also of critical importance. Our recent
work has focused on the importance of maintaining
endothelial function within transplanted organs as crit-
ical to successful preservation,3-9 especially of lungs
because the lung has a delicate alveolar and capillary
network. From data obtained through in vitro studies of
hypoxic and reoxygenated endothelial cells to serve as
a paradigm for the ischemic and reperfused vascular
milieu of lung transplantation, we designed a preserva-
tion solution10 that was based on the following consid-
erations. Hypoxia and reoxygenation significantly
increase permeability of endothelial monolayers,11
enhance leukocyte–endothelial cell interactions,12,13
and depress nitric oxide and cyclic adenosine
monophosphate (cAMP) levels (the former as a result
of quenching by superoxide generated during reoxy-
genation and the latter as a result of reduced adenylate
cyclase activity).14 The reperfusion period after organ
transplantation has been characterized as a time during
which nitric oxide levels plummet, with an attendant
reduction in tissue cyclic guanosine monophosphate
(cGMP) levels (as a result of reduced stimulation of
soluble guanylate cyclase by bioavailable nitric oxide)
and reduced cAMP levels, perhaps as the result of a
combined reduction in endothelial adenylate cyclase
activity and increase in types III and IV phosphodi-
esterase activity in vascular smooth muscle cells.
The deficiencies in these 2 pathways, nitric
oxide–cGMP and cAMP, are likely to be important rea-
sons underlying primary graft failure. During organ
preservation and reperfusion both cAMP and nitric
oxide play central roles in maintaining pulmonary vas-
cular homeostasis. cAMP helps to maintain control of
endothelial barrier function,14,15 endothelial cell–
leukocyte interactions,16,17 and vascular smooth muscle
tone.18 Nitric oxide, an important messenger that can
act in an autocrine or paracrine manner, also influences
vascular permeability,19 leukocyte–vessel wall interac-
tions,20 endothelial thrombogenicity,21 and vasomotor
tone by stimulating soluble guanylate cyclase to
increase cGMP. We hypothesized that supplementing
deficient cAMP and nitric oxide–cGMP pathways
might improve lung preservation for transplantation
and therefore designed a new storage solution that
could replenish these intercellular and intracellular
messengers. To investigate the efficacy of the new solu-
tion, we used a rat lung transplantation model to com-
pare it with other lung preservation solutions in com-
mon clinical or experimental use.
Methods
Rat orthotopic left lung transplantation model. Inbred
male Lewis rats (250-300 g) were used for all experiments
according to a protocol approved by the Institutional Animal
Care and Use Committee at Columbia University, in accor-
dance with guidelines of the American Association for the
Accreditation of Laboratory Animal Care. Donor rats were
given 500 units heparin intravenously and the pulmonary
artery was flushed with a 30-mL volume of 4°C preservation
solution at a constant pressure of 20 mm Hg (1 mm Hg = 133
Pa), with egress of preservation solution from the left atrium
during the flushing procedure facilitated by a large slit made
in the left atrium before flushing. The time required to infuse
the 30-mL volume of preservation solution under constant
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Euro-Collins solution, P < .01, 50% for University of Wisconsin solu-
tion, P < .05, 50% for low-potassium dextran glucose solution, P < .05,
and 13% for Columbia University solution without cyclic adenosine
monophosphate and nitroglycerin, P < .01). Conclusion: Nitroglycerin
and cyclic adenosine monophosphate confer beneficial vascular effects
that make Columbia University solution a superior lung preservation
solution in a stringent rat lung transplantation model. (J Thorac
Cardiovasc Surg 1999;118:135-44)
pressure was recorded as the “flushing time,” which served as
an index of pulmonary vascular resistance (PVR) during lung
harvest. The left lung was then excised, a cuff was placed on
each vascular and the bronchial stump, and the lung was sub-
merged for 6 hours at 4°C in a preservation solution of the
same composition as that used for flushing. Four different
preservation solutions were used; compositions are listed in
Table I. Columbia University solution, which contains a
cAMP analog, dibutyryl cAMP (db-cAMP) and nitroglyc-
erin, was prepared as described in our previous article.10 As
an additional control a version of Columbia University solution
was also prepared without either a cAMP analog or nitro-
glycerin. Euro-Collins solution was obtained from Baxter
Healthcare (Baxter Healthcare Corporation, Deerfield, Ill) and
modified by adding 10 mL 10% magnesium sulfate and 50 mL
50% glucose solution per 940 mL. University of Wisconsin
solution was obtained from Du Pont Pharmaceuticals (E. I.
du Pont de Nemours and Company, Wilmington, Del). Low-
potassium dextran glucose solution was prepared as de-
scribed in a previous report.22
Rats matched for sex, strain, and size were anesthetized,
intubated, and ventilated with 100% oxygen by means of a
rodent ventilator (Harvard Apparatus, Inc, Holliston, Mass).
Orthotopic left lung transplantation was performed through a
left thoracotomy by means of a rapid cuff technique for all 3
anastomoses, with warm ischemic times maintained at less
than 5 minutes. The hilar crossclamp was released, reestab-
lishing blood flow and ventilation to the transplanted lung.
The right lung was then functionally removed from the recip-
ient after reperfusion of the left lung and placement of the
flow and pressure measuring devices in the main pulmonary
artery (2F Millar catheter; Millar Instruments, Inc, Houston,
Tex) and around the main pulmonary artery (2-mm Doppler
Flow Probe; Transonic Systems, Inc, Ithaca, NY). This model
was adopted on the basis of previously published procedures.3
Measurement of lung graft function. On-line hemody-
namic monitoring was accomplished with MacLab (McLab
Instruments, Boston, Mass) and a Macintosh IIci computer
(Apple Computer, Inc, Cupertino, Calif). Measured hemody-
namic parameters included pulmonary arterial pressure (in
millimeters of mercury) and pulmonary arterial flow (in mil-
liliters per minute). The PaO2 (in millimeters of mercury) was
measured during inspiration of 100% oxygen with a model
ABL-2 gas analyzer (Radiometer Medical A/S, Brønshøj,
Denmark). PVR, expressed as millimeters of mercury per
milliliter per minute, was calculated as follows: PVR = (mean
pulmonary arterial pressure – left atrial pressure)/mean pul-
monary arterial flow. After baseline measurements the native
right pulmonary artery was ligated and serial hemodynamic
measurements were taken every 5 minutes until 30 minutes or
recipient death. In addition to hemodynamic measurements,
arterial blood for gas analysis was sampled at baseline and at
either 30 minutes or the final time at which the recipient was
alive.
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Table I. Compositions of preservation solutions
University of Low-potassium Columbia 
Euro-Collins Wisconsin dextran glucose University 
solution solution solution solution
Base preservation solution
Potassium (mmol/L) 115 125 4 120
Sodium (mmol/L) 10 30 165 —
Magnesium (mmol/L) 8 5 2 5
Chloride (mmol/L) — — 101 —
Bicarbonate (mmol/L) 10 — — —
Phosphate (mmol/L) 100 25 34 25
Sulfate (mmol/L) 8 5 2 5
Gluconate (mmol/L) — — — 95
Lactobionate (mmol/L) — 100 — —
Colloid (g/L) — Hydroxyethyl starch, 50 Dextran-40, 20 Dextran 50
Glucose (mmol/L) 120 — 56 67
Additives
Adenosine (mmol/L) — 5 — 5
Allopurinol (mmol/L) — 1 — —
db-cAMP (mmol/L) — — — 2
Nitroglycerin (mg/mL) — — — 0.1
Butylated hydroxyanisole (m mol/L) — — — 50
Butylated hydroxytoluene (m mol/L) — — — 50
N-Acetylcysteine (mmol/L) — — — 0.5
Heparin (U/mL) — — — 10
Verapamil (m mol/L) — — — 10
Physical composition
pH 7.4 7.4 7.4 7.6
Osmolality (mOsm/L) 452 327 335 325
Myeloperoxidase assay. Thirty minutes after ligation of
the native right pulmonary artery, or at the time of recipient
death, the transplanted lung was removed, rinsed briskly in
physiologic saline solution, and snap frozen in liquid nitrogen
until the time of myeloperoxidase assay, which was per-
formed as described previously.6 Change in absorbance at
460 nm was measured across 30 seconds (increase in optical
density was linear during this time interval). Myeloperoxi-
dase activity was expressed as change in absorbance at 460
nm per minute.
Measurement of tumor necrosis factor a and inter-
leukin 1a . A heparinized blood sample was taken from the
recipient 30 minutes after ligation of the right pulmonary
artery, or at the time of recipient death, and was centrifuged
for 10 minutes at 14,000 rpm. The supernatant was recovered
and frozen at –80°C until the time of assay. Assays for tumor
necrosis factor a (TNF-a ) and interleukin 1a (IL-1a ) were
performed with enzyme-linked immunosorbent assays for rat
TNF-a and IL-1a according to procedures suggested by the
manufacturer (Genzyme Corporation, Cambridge, Mass).
Assays were performed in duplicate, with standards run each
time the assay was performed. The lower limits for detection in
these assays were 10 pg/mL for TNF-a and 15 pg/mL for IL-1a .
Statistics. Comparisons between groups were performed
with the Mann-Whitney U test. Animal survival data were
analyzed by contingency analysis with the c 2 statistic. Values
are expressed as mean ± SEM.
Results
For initial experiments we measured the amount of
time required to flush in a constant volume of preserva-
tion solution under constant pressure. This “flushing
duration” should reflect both the vasoconstriction that
occurs during lung harvest and the viscosity of the
infusate at the hypothermic temperatures used. Five
different preservation solutions were compared: Euro-
Collins solution, University of Wisconsin solution, low-
potassium dextran glucose solution, Columbia Uni-
versity solution, and Columbia University solution
without db-cAMP and nitroglycerin. All solutions tested
that contained “intracellular” levels of potassium (range
115-125 mmol/L for Euro-Collins solution, University
of Wisconsin solution, Columbia University solution,
and Columbia University solution without db-cAMP and
nitroglycerin) were associated with vasoconstriction
during harvest relative to that seen with low-potassium
dextran glucose solution (Fig 1). Of the solutions tested,
Columbia University solution required the longest time
to infuse, suggesting that vascular resistance during the
initial pulmonary flush with Columbia University solu-
tion is higher than that with other solutions (Fig 1), even
though Columbia University solution contains the
vasodilators nitroglycerin and db-cAMP.
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Fig 1. Effect of preservation solution composition on pul-
monary vascular resistance during lung harvest. After anes-
thesia, left atrium was vented and pulmonary artery was
flushed with 30-mL volume of indicated preservation solu-
tion (4°C) at constant infusion pressure of 20 mm Hg.
Flushing duration (in seconds) was measured as index of har-
vest pulmonary vascular resistance. EC, Euro-Collins solu-
tion; UW, University of Wisconsin solution; LPDG, low-
potassium dextran glucose solution; CU, Columbia
University solution; CU(–), Columbia University solution
without db-cAMP and nitroglycerin. Compositions of these
solutions are described in Table I. For each group N = 8.
Boxes represent means; error bars indicate SEM.
Fig 2. Effect of preservation solution composition on arterial
oxygenation after lung transplantation. Donor lungs were
harvested and preserved with indicated solution for 6 hours at
4°C and transplanted orthotopically into strain-matched
recipient. After transplantation native right pulmonary artery
was ligated, and 30 minutes later (or just before recipient
death), 200 m L left ventricular blood was obtained to deter-
mine arterial oxygenation. EC, Euro-Collins solution; UW,
University of Wisconsin solution; LPDG, low-potassium dex-
tran glucose solution; CU, Columbia University solution;
CU(–), Columbia University solution without db-cAMP and
nitroglycerin. For each group N = 8. Boxes represent means;
error bars indicate SEM.
Because in previous work we showed that other prop-
erties of lung preservation solutions, especially those
that preserve endothelial homeostasis, are of greater
importance than their effects to reduce harvest pul-
monary vascular resistance, harvested lungs were
transplanted to determine the relative preservative
effects of these 4 preservation solutions. For these
experiments, after the initial flush lungs were
immersed for 6 hours at 4°C in a preservation solution
of identical composition to that used for flushing, after
which they were transplanted in an extremely stringent
orthotopic rat left lung transplantation model that we
have previously reported.23 Immediately after the vas-
cular and bronchial anastomoses were completed the
nontransplanted right lung was effectively removed
from the pulmonary circulation by ligation of the right
pulmonary artery. In this way the lung graft recipient
was forced to survive solely on the basis of the function
of the transplanted lung. The 5 different preservation
solutions (Euro-Collins solution, University of
Wisconsin solution, low-potassium dextran glucose
solution, Columbia University solution, and Columbia
University solution without db-cAMP or nitroglycerin)
differed markedly in ability to preserve lungs. In
groups that received lungs preserved with Euro-Collins
solution, University of Wisconsin solution, low-potas-
sium dextran glucose solution, and Columbia
University solution without db-cAMP or nitroglycerin,
arterial oxygenation was poor after transplantation
(PaO2 95 ± 22 mm Hg, 172 ± 55 mm Hg, 76 ± 15 mm
Hg, and 82 ± 25 mm Hg, respectively; Fig 2). In con-
trast, arterial oxygenation after transplantation of lungs
preserved in Columbia University solution was signifi-
cantly greater (PaO2 355 ± 25 mm Hg, P < 0.05 versus
all other groups; Fig 2).
Another critical reason for early recipient death
stems from flow limitation through the pulmonary vas-
cular bed. To evaluate this possibility, pulmonary vas-
cular resistance was determined after lung transplanta-
tion through simultaneous measurements of pulmonary
arterial flow and pressure. Animals that received lungs
preserved with Euro-Collins solution, University of
Wisconsin solution, low-potassium dextran glucose
solution, and Columbia University solution without db-
cAMP or nitroglycerin demonstrated significant limita-
tion of flow to the graft (6.2 ± 2.5 mL/min, 5.1 ± 2.4
mL/min, 7.2 ± 3.0 mL/min, and 4.1 ± 1.7 mL/min,
respectively) despite relative preservation of pul-
monary arterial pressures. This resulted in markedly
elevated PVR after transplantation (Fig 3). In sharp
contrast, grafts that had been preserved with Columbia
University solution and transplanted in an identical
manner demonstrated relatively well-preserved pul-
monary arterial pressure and flow (20.7 ± 1.0 mL/min,
P < .01 versus all other groups), resulting in low pul-
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Fig 3. Effect of preservation solution composition on PVR
after lung transplantation. Experiments were performed as
described in legend to Fig 2. PVR was calculated as
described in text. EC, Euro-Collins solution; UW, University
of Wisconsin solution; LPDG, low-potassium dextran glu-
cose solution; CU, Columbia University solution; CU(–),
Columbia University solution without db-cAMP and nitro-
glycerin. For each group N = 8. Boxes represent means; error
bars indicate SEM.
Fig 4. Effect of preservation solution composition on graft
neutrophil accumulation after lung transplantation. Experi-
ments were performed as described in legend to Fig 2. Lungs
were removed at 30 minutes after right pulmonary arterial
ligation (or at recipient death if it preceded 30-minute time
point), snap frozen in liquid nitrogen, and kept at –80°C until
time of assay. Myeloperoxidase activity, as change in ab-
sorbance (D Abs) at 460 nm per minute, was used to quantify
neutrophil accumulation. EC, Euro-Collins solution; UW,
University of Wisconsin solution; LPDG, low-potassium dex-
tran glucose solution; CU, Columbia University solution;
CU(–), Columbia University solution without db-cAMP and
nitroglycerin. For each group N = 8. Boxes represent means;
error bars indicate SEM.
monary vascular resistance (1 ± 0.2 mm Hg · mL–1 ·
min–1, P < .05 versus all other groups), an important
hallmark of well-preserved pulmonary grafts (Fig 3).
Experiments next investigated the proinflammatory
and cytokine milieu as a potential surrogate marker and
likely mediator of graft injury. Because neutrophils that
accumulate in the transplanted graft microvasculature
can contribute to flow limitations as well as to inflam-
matory up-regulation and tissue injury, the accumula-
tion of neutrophils was measured by myeloperoxidase
assay. Myeloperoxidase, a neutrophil-specific enzyme
that transforms hydrogen peroxide into highly toxic
oxygen metabolites, can be measured with a chro-
mogenic assay that enables neutrophil accumulation to
be quantified. These experiments demonstrated a
reduction in graft leukostasis of approximately 44% in
the Columbia University solution group with respect to
the other groups (Fig 4), which is not surprising
because both nitrovasodilators and cAMP analogs
reduce endothelial adhesive properties for leukocytes.
Because stimulation of the cAMP second-messenger
pathway also reduces TNF-a release by endothelial
cells, TNF-a levels were measured in recipient plasma.
As predicted, Columbia University solution, which
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Fig 5. Effect of preservation solution composition on recipi-
ent TNF-a levels after lung transplantation. Experiments
were performed as described in legend to Fig 2. Heparinized
blood samples were taken from left ventricle at 30 minutes
after right pulmonary arterial ligation (or at recipient death if
it preceded 30-minute time point). After centrifugation to
remove cellular elements, plasma was assayed for TNF-a by
enzyme-linked immunosorbent assay. EC, Euro-Collins solu-
tion; UW, University of Wisconsin solution; LPDG, low-
potassium dextran glucose solution; CU, Columbia
University solution; CU(–), Columbia University solution
without db-cAMP and nitroglycerin. For each group N = 8
blood samples assayed in duplicate. Boxes represent means;
error bars indicate SEM.
Fig 6. Effect of preservation solution composition on recipi-
ent IL-1a levels after lung transplantation. Experiments were
performed as described in legend to Fig 2. Heparinized blood
samples were taken from left ventricle at 30 minutes after
right pulmonary arterial ligation (or at recipient death if it
preceded 30-minute time point). After centrifugation to
remove cellular elements, plasma was assayed for IL-1a by
enzyme-linked immunosorbent assay. For each group N = 8
blood samples assayed in duplicate. EC, Euro-Collins solu-
tion; UW, University of Wisconsin solution; LPDG, low-
potassium dextran glucose solution; CU, Columbia Uni-
versity solution; CU(–), Columbia University solution
without db-cAMP and nitroglycerin. Boxes represent means;
error bars indicate SEM.
Fig 7. Effect of preservation solution composition on recipi-
ent survival after lung transplantation. Experiments were per-
formed as described in legend to Fig 2; after ligation of con-
tralateral (right) pulmonary artery (PA), time was recorded
until recipient death or until previously specified killing time
at 30 minutes. Death was defined a priori as a pulmonary
arterial flow of zero. Number of surviving recipients (numer-
ator) and total number of transplantation experiments
(denominator) are shown for each preservation solution. EC,
Euro-Collins solution; UW, University of Wisconsin solution;
LPDG, low-potassium dextran glucose solution; CU,
Columbia University solution; CU(–), Columbia University
solution without db-cAMP and nitroglycerin. Asterisk indi-
cates P = .021 versus University of Wisconsin solution and
low-potassium dextran glucose solution, P = .007 versus
Euro-Collins solution.
contains the cAMP analog db-cAMP, markedly attenu-
ated recipient plasma TNF-a levels compared with
those seen in recipients of lungs preserved in Euro-
Collins solution or University of Wisconsin solution
(Fig 5). An unexpected finding was that TNF-a levels
were also low in recipients of grafts preserved in low-
potassium dextran glucose solution. We recently
showed that IL-1a synthesized and released directly
from ischemic cardiac grafts is an important mecha-
nism in the autoamplification of local leukocyte
recruitment and inflammation,37 so we measured IL-
1 a levels to determine whether preservation with
Columbia University solution might exert some of its
beneficial effects by lowering IL-1a levels. Among all
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A B
C D
Fig 8. A, Effect of preservation time on arterial oxygenation after lung transplantation. Grafts were preserved in
Columbia University solution at 4°C for indicated durations, after which they were transplanted orthotopically
into strain-matched recipients. At 30 minutes after ligation of native right pulmonary artery or at recipient death,
200 m L blood was sampled from left ventricle for blood gas analysis. N = 8, N = 8, N = 3, N = 3, and N = 6 trans-
plants for preservation durations of 6, 9, 12, 15, and 18 hours, respectively. B, Effect of preservation time on PVR
after lung transplantation. Grafts were preserved in Columbia University solution at 4°C for indicated durations,
after which they were transplanted orthotopically into strain-matched recipients. At 30 minutes after ligation of
native right pulmonary artery or at recipient death, PVR was measured as described in legend to Fig 3. N = 8, N
= 8, N = 3, N = 3, and N = 6 transplants for preservation durations of 6, 9, 12, 15, and 18 hours, respectively. C,
Effect of preservation time on graft neutrophil accumulation after lung transplantation. Grafts were preserved in
Columbia University solution at 4°C for indicated durations, after which they were transplanted orthotopically
into strain-matched recipients. At 30 minutes after ligation of native right pulmonary artery or at recipient death,
lung tissue was obtained and myeloperoxidase activity was measured as described in the legend to Fig 4. N = 8,
N = 8, N = 3, N = 3, and N = 6 transplants for preservation durations of 6, 9, 12, 15, and 18 hours, respectively.
D, Effect of preservation time on recipient survival after lung transplantation. Grafts were preserved in Columbia
University solution at 4°C for indicated durations, after which they were transplanted orthotopically into strain-
matched recipients. Immediately after transplantation native (right) pulmonary artery was ligated, and time until
recipient death was recorded. Survivals at 30 minutes are shown. N = 8, N = 8, N = 3, N = 3, and N = 6 trans-
plants for preservation durations of 6, 9, 12, 15, and 18 hours, respectively.
groups studied, local IL-1a levels were lowest in recip-
ients of grafts preserved with Columbia University
solution (Fig 6).
This in vivo lung transplantation model provides the
opportunity to use recipient survival as an objective
means of summing up the multiple effects of the preser-
vation solutions on the various surrogate end points that
we have measured in vitro (harvest vascular resistance,
hemodynamic and functional characteristics of the
graft, and cytokine levels) in addition to other, unmea-
sured factors. These data, in which survival time after
exclusion of the nontransplanted lung from the pul-
monary circulation was recorded for the pre-determined
30-minute period, demonstrated that preserving lungs
with Columbia University solution permitted optimal
recipient survival compared with the other tested
groups (Fig 7). To push the threshold of ischemic injury
in this model to test the ability of Columbia University
solution to preserve grafts, experiments were per-
formed in which the period of hypothermic preserva-
tion was extended for as long as 18 hours (groups of
experiments were performed in 3-hour increments of
hypothermic ischemia). These experiments demon-
strated that Columbia University solution maintained
its excellent preservative properties when preservation
duration was extended to 9 hours; however, lung graft
preservation was poor in this model for periods of 12
hours or longer, even with Columbia University solu-
tion (Fig 8, A through D).
Discussion
During the processes of harvesting and then trans-
planting a lung, all cells within the graft are subjected to
an obligate period of ischemia followed by reperfusion.
Because of the rich vascularity of the lung, maintenance
of homeostasis in the pulmonary endothelial cells
(which comprise nearly 30% of the pulmonary
parenchymal mass)24 is especially critical for successful
lung preservation. Two cyclic nucleotides, cGMP and
cAMP, are critical intermediaries in multiple aspects of
vascular homeostasis; both prevent leukocyte adhesion
to endothelium, maintain endothelial barrier properties,
are potent vasodilators, and can inhibit platelet reactivi-
ty and thrombosis. Both cAMP levels9 and nitric oxide
(and consequently cGMP) levels5 decline markedly dur-
ing pulmonary reperfusion, so it is surprising that no
lung preservation strategy currently in clinical use
attempts to buttress either of these pathways.
In this work we hypothesized that supplementing defi-
cient cAMP and nitric oxide–cGMP second-messenger
systems by adding a membrane-permeable cAMP ana-
log and nitroglycerin to a preservation solution of our
own design (Columbia University solution) might
improve lung preservation for transplantation. To test
this hypothesis these experiments were designed to
compare the effects of established lung preservation
solutions and Columbia University solution with
respect to a number of salient vascular properties, func-
tional characteristics, and cytokine profiles of lung
grafts and lung transplantation recipients. These results
unequivocally show that Columbia University solution
is a superior preservative in the isogeneic orthotopic rat
lung transplantation model. When compared with Euro-
Collins solution, low-potassium dextran glucose solu-
tion, and University of Wisconsin solution, only
Columbia University solution consistently inhibited the
accumulation of neutrophils, reduced recipient levels of
proinflammatory cytokines, improved lung graft func-
tion, and was associated with high recipient survival.
These studies are especially important in light of the
fact that 77% of all lung transplantation centers world-
wide use Euro-Collins preservation solution and 14%
use University of Wisconsin solution (although none
use low-potassium dextran for flush perfusion, 1 center
flushes grafts with Euro-Collins solution and stores
them in low-potassium dextran solution).25 Although
Columbia University solution has ingredients other than
those that preserve endothelial properties, deletion
experiments performed when testing Columbia Uni-
versity solution in a rat cardiac transplantation model
suggested that nitroglycerin and the cAMP analog were
among the 2 most critical ingredients.10 These findings
are supported by these experiments, in which a version
of Columbia University solution was prepared that was
devoid of db-cAMP and nitroglycerin; this deleted solu-
tion was a poor pulmonary preservative.
Previous mechanistic studies in the same lung trans-
plantation model have been instructional in terms of
defining mechanisms whereby nitroglycerin and db-
cAMP act to enhance lung preservation. In addition to
being potent pulmonary vasodilators, these agents both
reduce graft platelet accumulation, edema, and
leukostasis.8,9 There are multiple mechanisms through
which stimulation of the cAMP pathway may inhibit
leukocyte accumulation26; elevating intracellular cAMP
inhibits mobilization and expression of the b 2 integrin
CD11b/CD18 on the neutrophil surface, as well as
shape change of the neutrophil.27 It is possible that qual-
itative changes or reduced expression of CD11b/CD18
may underlie the antiadhesive actions of cAMP for neu-
trophils. Nitric oxide donors also have been studied in
depth with respect to their ability to inhibit leukocyte
adhesion. Although multiple mechanisms may be
involved, a mechanism of particular relevance for lung
transplantation is the quenching effect of nitric oxide for
superoxide, which is a potent neutrophil chemoattrac-
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tant28 that is generated in abundance in the lung reper-
fusion milieu.5 Furthermore, nitric oxide donors appear
to reduce expression of P-selectin at the reoxygenated
endothelial surface.29,30 This latter property may be of
especial relevance to lung transplantation, because lung
preservation induces P-selectin–mediated leukocyte
sequestration that thereby injures the pulmonary graft
shortly after reperfusion.6
It is interesting to note that in these experiments,
Columbia University solution did not exhibit the prop-
erties of a harvest vasodilator, which may reflect a com-
bination of the high-potassium base solution (which can
vasoconstrict) and the high viscosity of the hypothermic
solution caused by the dextran. Nevertheless, previous
work has shown that harvest vasodilation by itself is
insufficient to preserve lungs, because such potent har-
vest vasodilators as hydralazine and minoxidil fail to
protect the lungs when given during the initial pul-
monary flush as a prelude to hypothermic storage.8,9
The rationale behind the use of a cell-permeable
cAMP analog stems from in vitro observations with
cultured endothelial cells exposed to hypoxia and
reoxygenation as an in vitro paradigm for the ischemia
and reperfusion of transplantation. Endothelial cells
exposed to hypoxia exhibit a decline in intracellular
levels of cAMP,14 with attendant changes in the actin-
based cytoskeleton and loss of monolayer properties as
a relatively impermeable barrier. Addition of mem-
brane-permeable cAMP analogs that are not subject to
hydrolysis, such as db-cAMP, can drive the endothelial
phenotype toward normal under conditions of hypox-
ia14 or when ambient levels of TNF-a are elevated.31
Although intracellular cAMP can be increased in a
number of alternative ways, such as by inhibiting its
catabolism with specific cAMP-phosphodiesterases,
addition of db-cAMP to a preservation solution seems
to be a particularly effective strategy for improving
lung preservation. In addition, in vitro studies have
shown cAMP analogs such as db-cAMP or 8-bromo-
cAMP to inhibit the LPS-mediated induction of the
proinflammatory cytokines TNF-a and interleukin-
1b 32,33 and to maintain endothelial anticoagulant prop-
erties by preventing the hypoxia-mediated suppression
of thrombomodulin.31 It has also been reported that db-
cAMP blocks the accumulation of TNF-a transcripts,
although in these studies it did not affect the expression
of IL-1a .34,35 These in vitro data provide insights into
how Columbia University solution may have reduced
levels of the proinflammatory cytokines IL-1a and
TNF-a in the lung graft recipients.
Nitric oxide, produced in abundance by the lungs,
also has an important role in maintaining vascular
homeostatic properties, preventing neutrophil adher-
ence to the endothelium,20 maintaining endothelial bar-
rier properties,19 inhibiting platelet aggregation,4,21 and
modulating pulmonary vasomotor tone.36 Because
nitric oxide levels fall abruptly at the onset of reperfu-
sion (as a result of quenching by superoxide),5 we
hypothesized that the addition of a nitric oxide donor
nitroglycerin to the pulmonary preservation solution
might help to preserve vascular homeostasis. In previ-
ous work we demonstrated that nitroglycerin improves
lung preservation in a dose-dependent fashion by
improving blood flow, reducing leukocyte and platelet
accumulation, and improving gas exchange in the lung
transplantation recipient.8
On the basis of these considerations of Columbia
University solution’s ability to maintain endothelial
homeostasis by virtue of 2 ingredients added specifi-
cally for this purpose, it is not surprising that lungs pre-
served in it and the recipients of Columbia University
solution–preserved grafts fared better in virtually every
respect than did their counterparts treated with the
other preservation solutions. These studies do not
negate an important role for other considerations of
preservation solution composition, such as colloids,
antioxidants, electrolytes, or impermeant anions. In
fact, multiple previous important studies have led to the
characterization of many of these additives as critical
for a successful preservation solution. Building on this
base of knowledge we designed Columbia University
solution to go a step further, focusing on 2 additives
that improve endothelial function.
The studies presented here demonstrate that lung
preservation with Columbia University solution results
in optimal graft hemodynamic and functional charac-
teristics, as well as reduced neutrophil infiltration and
cytokine levels. Columbia University solution, which
contains agents that preserve vascular homeostasis, is
superior to other clinically used lung preservation solu-
tions in the rat orthotopic lung transplantation model.
These studies show that Columbia University solution
warrants testing in larger animals and possibly even in
humans.
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